ArticleOncology letters2015
Article in Oncology letters, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 17 citations in OpenAlex.
- Metabolite changes in oral tumours and cysts: a narrative review.BMC oral health · 2025Review
- Transcriptome profiling and metabolic pathway analysis towards reliable biomarker discovery in early-stage lung cancer.Journal of applied genetics · 2025Article
- Article
- NMR Metabolomics and Chemometrics of Commercial Varieties ofPlants (Basel, Switzerland) · 2024Article
- Construction of the XGBoost model for early lung cancer prediction based on metabolic indices.BMC medical informatics and decision making · 2023Article
- Response of Osteosarcoma Cell Metabolism to Platinum and Palladium Chelates as Potential New Drugs.Molecules (Basel, Switzerland) · 2021Article
- Early lung cancer diagnostic biomarker discovery by machine learning methods.Translational oncology · 2021Article
- Metabolic landscape of oral squamous cell carcinoma.Metabolomics : Official journal of the Metabolomic Society · 2020Review
- Metabolomics study of oral cancers.Metabolomics : Official journal of the Metabolomic Society · 2019Review
- Non-targeted and targeted metabolomics approaches to diagnosing lung cancer and predicting patient prognosis.Oncotarget · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A major obstacle of successful chemotherapy is the development of multidrug resistance (MDR) in the cancer cells, which is difficult to reverse. Metabolomic analysis, an emerging approach that has been increasingly applied in various fields, is able to reflect the unique chemical fingerprints of specific cellular processes in an organism. The assessment of such metabolite changes can be used to identify novel therapeutic biomarkers. In the present study,
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.